Research programme: PARP-1 inhibitors - IMPACT Therapeutics

Drug Profile

Research programme: PARP-1 inhibitors - IMPACT Therapeutics

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IMPACT Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in China (PO)
  • 25 Feb 2016 Research programme: PARP-1 inhibitors - IMPACT Therapeutics is available for licensing as of 25 Feb 2016.
  • 25 Feb 2016 IMPACT Therapeutics has patent protection for its PARP-1 inhibitors in China (Company website-Feb 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top